Focused On-demand Library for Mediator of RNA polymerase II transcription subunit 13-like

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q71F56

UPID:

MD13L_HUMAN

Alternative names:

Mediator complex subunit 13-like; Thyroid hormone receptor-associated protein 2; Thyroid hormone receptor-associated protein complex 240 kDa component-like

Alternative UPACC:

Q71F56; A1L469; Q68DN4; Q9H8C0; Q9NSY9; Q9UFD8; Q9UPX5

Background:

The Mediator of RNA polymerase II transcription subunit 13-like, also known as Mediator complex subunit 13-like, plays a pivotal role in the transcription of RNA polymerase II-dependent genes. It acts as a bridge, facilitating the transfer of information from gene-specific regulatory proteins to the basal RNA polymerase II transcription machinery. This protein is integral in assembling a functional preinitiation complex, crucial for transcription initiation. It has a specific regulatory role in the transcription of targets within the Wnt and SHH signaling pathways.

Therapeutic significance:

The protein's involvement in a syndrome characterized by intellectual disability, delayed development, language impairment, and distinctive facial features, with variable cardiac defects, underscores its therapeutic significance. Understanding the role of Mediator of RNA polymerase II transcription subunit 13-like could open doors to potential therapeutic strategies for this syndrome.